While Alzheimer's has long reigned as one of the most challenging fields in R&D, it has also provided some of the most confident projections in the industry. And now Lundbeck is joining the ranks of the optimists.
Cubist Pharmaceuticals' in-development antibiotic aced the second leg of its Phase III program, the company said, paving the way for an FDA application and bumping its shares up another 9%.
NIH Director Francis Collins plans to start off 2014 with a New Year's resolution to spend more of the institute's bucks backing the most promising investigators, shifting some money away from the project grants that dominate its approach to backing high-risk early-stage research.
Preclinical CRO Charles River Laboratories is shuffling its high offices in an effort to better focus on efficiency, uniting its business units to slash spending and speed up growth.
The cancer immunotherapy biotech Agenus has continued its march back from a big R&D setback earlier in the year, seeing its share price spike 36% this morning after posting positive results for a single-arm Phase II study of one of its brain cancer vaccines.
Belgium's Genae has expanded its European footprint, cutting the ribbon on a Swiss office with its eye on a bigger share of the market for medical device development.
Aveo Oncology's long-troubled tivozanib is unlikely to meet its primary endpoint in a study on colorectal cancer, the company said, sending the biotech back to the drawing board after a high-profile failure in kidney cancer.
When Roche reviewed its big drug pipeline last fall, the pharma giant started its review of an ambitious and wide-ranging set of programs for Alzheimer's disease with a mention of RG7129, an early-stage BACE inhibitor that held the promise of preventing the production of amyloid beta, the toxic protein that figures prominently among the likely causes of Alzheimer's.
Back in January, Jeremy Levin--then riding high as CEO of Teva--didn't think much of the company's program for an immune checkpoint receptor drug dubbed CT-011, or pidilizumab. Now Levin is out, and those checkpoint receptor drugs have emerged as one of the hottest R&D arenas in the industry.
Duke University leads the way among schools with on-campus CROs, and now Oxygen Biotherapeutics has entrusted the institution with handling late-stage studies of its promising heart drug.